"Epoprostenol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
| Descriptor ID |
D011464
|
| MeSH Number(s) |
D10.251.355.255.550.550.500 D23.469.050.175.725.550.500
|
| Concept/Terms |
Epoprostenol- Epoprostenol
- PGI2
- Prostaglandin I2
- Prostacyclin
- Prostaglandin I(2)
- Epoprostanol
- PGX
Epoprostenol Sodium- Epoprostenol Sodium
- Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
|
Below are MeSH descriptors whose meaning is more general than "Epoprostenol".
Below are MeSH descriptors whose meaning is more specific than "Epoprostenol".
This graph shows the total number of publications written about "Epoprostenol" by people in this website by year, and whether "Epoprostenol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epoprostenol" by people in Profiles.
-
Weir NA, Saiyed R, Alam S, Conrey A, Desai HD, George MP, Keeley JH, Klings ES, Mehari A, Taylor JG, Minniti CP, Kato GJ. Prostacyclin-analog therapy in sickle cell pulmonary hypertension. Haematologica. 2017 05; 102(5):e163-e165.
-
Russell-Puleri S, Dela Paz NG, Adams D, Chattopadhyay M, Cancel L, Ebong E, Orr AW, Frangos JA, Tarbell JM. Fluid shear stress induces upregulation of COX-2 and PGI2 release in endothelial cells via a pathway involving PECAM-1, PI3K, FAK, and p38. Am J Physiol Heart Circ Physiol. 2017 Mar 01; 312(3):H485-H500.
-
Bayorh M, Rollins-Hairston A, Adiyiah J, Lyn D, Eatman D. Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase. J Renin Angiotensin Aldosterone Syst. 2012 Sep; 13(3):353-9.
-
L?pez-Candales A, Cleary H, Edelman K. Constrictive-like physiology in severe pulmonary hypertension: the effect of the Valsalva maneuver. South Med J. 2011 Apr; 104(4):282-4.
-
Beales IL, Ogunwobi OO. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer. 2010 May 01; 126(9):2247-55.
-
Bayorh MA, Layas MF, Mann G, Feuerstein GZ, Eatman D. The effect of diet on simvastatin and losartan enhancement of endothelial function. Clin Exp Hypertens. 2007 Jul; 29(5):311-25.
-
Pahakis MY, Kosky JR, Dull RO, Tarbell JM. The role of endothelial glycocalyx components in mechanotransduction of fluid shear stress. Biochem Biophys Res Commun. 2007 Mar 30; 355(1):228-33.
-
Bayorh MA, Mann G, Walton M, Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. Clin Exp Hypertens. 2006 Feb; 28(2):121-32.
-
Ganafa AA, Walton M, Eatman D, Abukhalaf IK, Bayorh MA. Amlodipine attenuates oxidative stress-induced hypertension. Am J Hypertens. 2004 Sep; 17(9):743-8.
-
Bayorh MA, Ganafa AA, Socci RR, Silvestrov N, Abukhalaf IK. The role of oxidative stress in salt-induced hypertension. Am J Hypertens. 2004 Jan; 17(1):31-6.